Shixia Guan

Shixia Guan


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
QRQiuhong Rao
Qiuhong Rao
ZQZhenwen Qiu
Zhenwen Qiu
DHDeen Huang
Deen Huang
TLTiejun Lu
Tiejun Lu
ZZZhenyu Jason Zhang
Zhenyu Jason Zhang
QLQingguo Li
Qingguo Li

12 August 2014 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
PDF file
YMYan Ma
Yan Ma
HLHaiGang Li
HaiGang Li
SGShixia Guan
Shixia Guan
Aim to design an effective breviscapine nanoscale drug delivery system to realize the improvement of its oral bioavailability. Based on the investigations of the stabilities in the gastrointestinal tract (GIT), permeation and efflux across the cell membrane, the breviscapine nanoemulsion (NE) was formulated and evaluated in vitro and in vivo. The globule size and polydispersity index of the NE was 45.6 nm and 0.105, and the efficient encapsulation was 95.2%. In vitro, the drug release from NEs in pH 6.8 PBS fit to the first-order kinetics. The Caco-2 cell transport experiments showed that the breviscapine NE facilitated the improvement of the apparent permeability coefficient (Papp) from the apical side to basilar side compared with the free drug. In vivo, the relative bioavailability of breviscapine NE reached to 249.7%. All the studies implicated that the NE carrier contributed to the enhancement of the oral absorption of breviscapine due to the improved stability and permeation in the GIT. The nanoemulsions technology is better for the poor permeable and unstable active agents in GIT as well as helps the industrial scale process.

1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
DHDeen Huang
Deen Huang
ZXZiyuan Xie
Ziyuan Xie
QRQiuhong Rao
Qiuhong Rao
ELEvangelos Liamas
Evangelos Liamas
PPPiaopiao Pan
Piaopiao Pan
QLQingguo Li
Qingguo Li

17 February 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
XYXufeng Yang
Xufeng Yang
YPYongrui Peng
Yongrui Peng
YWYu-E Wang
Yu-E Wang
YZYuxiu Zheng
Yuxiu Zheng
YHYiming He
Yiming He
SGShixia Guan
Shixia Guan

22 December 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
YHYiming He
Yiming He
YHYihong Huang
Yihong Huang
HXHuahua Xu
Huahua Xu
XYXufeng Yang
Xufeng Yang
NLNan Liu
Nan Liu
SGShixia Guan
Shixia Guan

1 January 2020 in Drug Delivery
Verified
Journal Article
Open access
JZJunqiu Zhai
Junqiu Zhai
YWYu-E Wang
Yu-E Wang
XZXiangping Zhou
Xiangping Zhou
YMYan Ma
Yan Ma
SGShixia Guan
Shixia Guan
Schizophrenia and bipolar disorder are severe chronic neuropsychiatric diseases, affecting hundreds of millions of people worldwide. Asenapine maleate (ASM) has been demonstrated as a safe and effective therapeutic agent under twice-daily administration. However, lower compliance is observed when patients are treated with ASM, which significantly limits its application in schizophrenia and bipolar disorder. Moreover, the low bioavailability of ASM caused by first-pass metabolism and poor aqueous solubility also impairs the treatment effect. A formulation of ASM with the property of long-term sustained release and improved bioavailability can be a solution to overcome these weaknesses. In this article, we prepared ASM-loaded poly(lactic-co-glycolic acid) (ASM-PLGA) microspheres through different techniques, including emulsification-solvent evaporation (ESE), Shirasu porous glass membrane emulsification (SPG-ME), and microfluidic method. In vitro and in vivo assessments demonstrated that uniform-sized microspheres generated by the microfluidic process sustainably released ASM throughout 40-days, showing low burst release and significantly improved bioavailability. The results suggest that ASM-PLGA microspheres prepared by the microfluidic method provide an efficient strategy to enhance the drug exposure of ASM as the treatment of chronic neuropsychiatric diseases. It is also evident that this microfluidic strategy has the potential to construct with other drugs, establishing long-acting formulations.